Circio Holding ASA
TA50
Company Profile
Business description
Circio Holding ASA is a biotechnology company developing circular RNA expression technology for gene and cell therapy applications. It has developed a circular RNA (circRNA) vector expression platform known as circVec, which is based on modular genetic constructs designed for circRNA production within target cells. The platform is being developed for applications including genetic medicine, cell therapy, and chronic disease treatment. The company's activities also include the development of RNA, DNA, and viral therapeutic technologies related to gene expression and protein production.
Contact
c/o Mesh Community AS
Tordenskiolds Gate 2
Oslo0160
NORT: +47 92951788
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,845.60 | 51.40 | -0.58% |
| CAC 40 | 8,070.73 | 10.70 | -0.13% |
| DAX 40 | 25,384.48 | 117.95 | 0.47% |
| Dow JONES (US) | 51,524.15 | 174.17 | 0.34% |
| FTSE 100 | 10,689.58 | 9.59 | 0.09% |
| HKSE | 24,510.09 | 251.04 | -1.01% |
| NASDAQ | 26,995.55 | 56.18 | 0.21% |
| Nikkei 225 | 66,364.20 | 850.21 | 1.30% |
| NZX 50 Index | 13,811.11 | 13.72 | -0.10% |
| S&P 500 | 7,718.96 | 14.83 | 0.19% |
| S&P/ASX 200 | 8,665.00 | 37.00 | -0.43% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |